Abstracts: 5007, 3570, 4153, 4183, 8036, 8039, 8628, 11161, 5592, 6528, 9520, 1043, 1048, 1065, 3081, 5064, 4564

NEWS RELEASE

Approved for Distribution on May 22, 2025, at 5:01 p.m. ET

Foundation Medicine to Present Over 15 Abstracts at the 2025 ASCO® Annual Meeting

BOSTON – May 22, 2025 – Foundation Medicine, Inc., a genomic company committed to transforming cancer care, today announced that the company and its collaborators will present more than 15 abstracts demonstrating the value of high-quality biomarker tests to inform cancer care at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting from May 30 to June 3 in Chicago.

Foundation Medicine's research presented at the meeting will include new insights across breast cancer, lung cancer and prostate cancer, including an oral presentation highlighting the findings from the COMRADE phase 2 clinical trial in castration resistant prostate cancer, which leveraged the research use version of FoundationOne®Monitor, the company's tissue-free treatment response monitoring assay, for serial ctDNA analysis. (Abstract 5007, Tuesday, June 3, at 11:57 am – 12:09 pm CT, Hall D1)

"In partnership with over 30 clinical collaborators, Foundation Medicine's new research at the ASCO Annual Meeting further reinforces the important role high-quality biomarker testing plays in delivering personalized cancer care," said Mia Levy, Ph.D., M.D., chief medical officer at Foundation Medicine. "From exploring the role of innovative and complex biomarkers to expanding the clinical utility of genomic profiling, we are excited to demonstrate how our testing portfolio, including our new treatment response monitoring assay, can help providers make more informed treatment decisions for their patients."

To access the abstracts being presented at the 2025 ASCO Annual Meeting, please visit ASCO.org/abstracts.

Follow Foundation Medicine on LinkedIn, X and Instagram for more updates from #ASCO25 and visit us in person at booth #27021.

Complete list of Foundation Medicine's abstracts at the 2025 ASCO Annual Meeting

Abstract Number	Title	Product
	Saturday, May 31	
3570	Comparison of *MET* genomic alterations (GA) identified in colorectal cancer (CRC) vs gastric cancer (GCA)	FoundationOne®CDx

Abstracts: 5007, 3570, 4153, 4183, 8036, 8039, 8628, 11161, 5592, 6528, 9520, 1043, 1048, 1065, 3081, 5064, 4564

4153	Pancreatic adenosquamous carcinoma (PASC): A comparative genomic landscape study	FoundationOne®CDx
4183	*BRCA1/2* and *PALB2* short variants (SVs) contributed by clonal hematopoiesis (CH) in liquid biopsies (LBx) from patients with advanced pancreatic cancer (PC)	FoundationOne®CDx / FoundationOne®Liquid CDx
8036	Tumor type prediction via tissue- and liquid-based comprehensive genomic profiling: High-specificity tobacco signature detection to support lung cancer diagnosis	FoundationOne®CDx / FoundationOne®Liquid CDx
8039	Clinical utility of pathologist-directed comprehensive comparative molecular profiling for the classification of separate primary lung cancers vs. intrapulmonary metastasis	FoundationOne®CDx
8628	Association of circulating tumor DNA (ctDNA) variant allelic frequency (VAF) with outcomes on matched targeted therapies (TT) in advanced non-small cell lung cancer (aNSCLC)	FoundationOne®Liquid CDx
11161	Real-world analysis of factors influencing turnaround time (TAT) for tissue comprehensive genomic profiling (CGP) in non-small cell lung cancer (NSCLC)	FoundationOne®CDx
Sunday, June 1		
5592	Distinguishing tumor vs. clonal hematopoiesis (CH)–derived *TP53* and *BRCA1/2* alterations in ovarian cancer liquid biopsies with a predictive algorithm to inform clinical decision-making	FoundationOne®CDx / FoundationOne®Liquid CDx
6528	Nucleophosmin (*NPM1*) genomic alterations (GA) in acute myeloid leukemia (AML): A genomic landscape study	FoundationOne®Heme
9520	Homologous recombination deficiency signature (HRDsig) in advanced cutaneous melanoma (ACM): A genomic landscape study	FoundationOne®CDx
Monday, June 2		
1043	*TP53* genomic alterations including targetable *TP53* Y220C mutation in clinically advanced breast cancer	FoundationOne®CDx
1048	Genomic alterations (GAs) associated with durability of benefit from trastuzumab deruxtecan (T-DXd), trastuzumab emtansine (T-DM1) and sacituzumab govitecan (SG) in metastatic breast cancer (MBC)	FoundationOne®CDx / FoundationOne®Liquid CDx
1065	Quantifying the clinical impact of tissue reflex testing for liquid biopsy *ESR1* mutation-negative cases with low ctDNA tumor fraction (TF) in HR(+)HER2(-) breast cancer	FoundationOne®CDx / FoundationOne®Liquid CDx
3081	Genomic landscape of 5'methylthioadenosine phosphorylase (*MTAP*) deleted (*MTAP* loss) non-squamous carcinoma of unknown primary site (nsCUP)	FoundationOne®CDx

Abstracts: 5007, 3570, 4153, 4183, 8036, 8039, 8628, 11161, 5592, 6528, 9520, 1043, 1048, 1065, 3081, 5064, 4564

5064	Additive clinical utility of tissue biomarkers of microsatellite instability (MSI) status and tumor mutational burden (TMB) to predict immune checkpoint inhibitor (ICI) effectiveness for real-world patients with metastatic castration-resistant prostate cancer (mCRPC)	FoundationOne®CDx
4564	Fibroblast growth factor receptor 3 (*FGFR3*) alteration status and outcomes with immune checkpoint inhibitors (ICPI) in patients with metastatic urothelial carcinoma	FoundationOne®CDx
Tuesday, June 3		
5007	A multicenter, randomized, phase 2, investigator-initiated ETCTN trial of olaparib + radium-223 vs. radium-223 in men with castration-resistant prostate cancer (CRPC) with bone metastases (BM) (COMRADE): Initial efficacy and biomarker analysis	Research use version of FoundationOne®Monitor*

About Foundation Medicine

Foundation Medicine is a genomics company dedicated to transforming cancer care. We develop high-quality diagnostic tests that accurately identify the genomic mutations driving a patient's cancer, match a patient to the most effective treatment options, including targeted therapies, immunotherapies or clinical trials, and monitor a patient's response to treatment. For more information, please visit us on www.FoundationMedicine.com and follow us on LinkedIn, Instagram, X and YouTube.

About FoundationOne®CDx

FoundationOne®CDx is a next-generation sequencing based in vitro diagnostic device for detection of substitutions, insertion and deletion alterations (indels), and copy number alterations (CNAs) in 324 genes and select gene rearrangements, as well as genomic signatures including microsatellite instability (MSI) and tumor mutational burden (TMB) using DNA isolated from formalin-fixed, paraffin-embedded (FFPE) tumor tissue specimens. FoundationOne CDx is for prescription use only and is intended as a companion diagnostic to identify patients who may benefit from treatment with certain targeted therapies in accordance with their approved therapeutic product labeling. Additionally, FoundationOne CDx is intended to provide tumor mutation profiling to be used by qualified health care professionals in accordance with professional guidelines in oncology for patients with solid malignant neoplasms. Use of the test does not guarantee a patient will be matched to a treatment. A negative result does not rule out the presence of an alteration. Some patients may require a biopsy. For a full list of targeted therapies for which FoundationOne CDx is indicated as a companion diagnostic, please visit www.F1CDxLabel.com.

Abstracts: 5007, 3570, 4153, 4183, 8036, 8039, 8628, 11161, 5592, 6528, 9520, 1043, 1048, 1065, 3081, 5064, 4564

About FoundationOne®Liquid CDx

FoundationOne®Liquid CDx is a qualitative next generation sequencing based in vitro diagnostic test for prescription use only that uses targeted high throughput hybridization-based capture technology to analyze 324 genes utilizing circulating cell-free DNA (cfDNA) isolated from plasma derived from anti-coagulated peripheral whole blood of advanced cancer patients. The test is FDA-approved to report short variants in over 300 genes and is a companion diagnostic to identify patients who may benefit from treatment with specific therapies (listed in Table 1 of the Intended Use) in accordance with the approved therapeutic product labeling. Additional genomic findings may be reported and are not prescriptive or conclusive for labeled use of any specific therapeutic product. Use of the test does not guarantee a patient will be matched to a treatment. A negative result does not rule out the presence of an alteration. Patients who are negative for companion diagnostic mutations should be reflexed to tumor tissue testing and genomic alteration status confirmed using an FDA-approved tumor tissue test, if feasible. For the complete label, including companion diagnostic indications and complete risk information, please visit www.F1LCDxLabel.com.

About Foundation®Heme

FoundationOne®Heme is a laboratory developed test that was developed and its performance characteristics determined by Foundation Medicine. FoundationOne Heme has not been cleared or approved by the U.S. Food and Drug Administration. For more information on FoundationOne Heme, please see its Technical Specifications at foundationmedicine.com/heme.

The test employs RNA sequencing in addition to DNA sequencing to simultaneously detect all classes of genomic alterations, including base pair substitutions, insertions and deletions, copy number alterations and rearrangements, and gene fusions.

Media Contact:
Danielle Johns, 845-304-7408
newsroom@foundationmedicine.com

*For Research Use Only. Not for use in diagnostic procedures.